Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RD 133

Next Previous
X
Search
Drug Profile

RD 133

Alternative Names: RD-133

Latest Information Update: 06 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanjing IASO Biotherapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 29 Dec 2021 Shanghai IASO Biotechnology initiates enrolment in the early phase I trial for Solid tumors (Second-line or greater) in China (NCT05166070)
  • 02 Dec 2021 Shanghai IASO Biotechnology plans a early phase I trial for Solid tumours (Second-line therapy or greater) in China (IV, Infusion) (NCT05141253)
  • 24 Sep 2021 Phase-I clinical trials in Solid tumours in China (Parenteral) prior to September 2021 (Nanjing IASO Biotherapeutics pipeline, September 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top